Edition:
United States

Profile: Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

43.18USD
4:02pm EDT
Change (% chg)

$-0.21 (-0.48%)
Prev Close
$43.39
Open
$43.49
Day's High
$43.58
Day's Low
$43.04
Volume
118,146
Avg. Vol
85,238
52-wk High
$68.00
52-wk Low
$40.74

Search Stocks

Dr. Reddy's Laboratories Limited, incorporated on February 24, 1984, is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as API or bulk drugs. Proprietary Products segment consists of its differentiated formulations business, its new chemical entities (NCEs) business, and its dermatology focused specialty business operated through Promius Pharma. Others include the operations of its wholly owned subsidiary, Aurigene Discovery Technologies Limited, a discovery-stage biotechnology company developing therapies in the fields of oncology and inflammation.

Global Generics

Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of its biologics business. The segment is divided in branded and unbranded drug products. Its Global generics segment includes various regions, such as India, Russia and Other Countries of the Former Soviet union, North America (the United States and Canada), Europe and Rest of the World market. Its Rest of the World markets include Venezuela, South Africa and Australia. In India, its key therapeutic categories include gastro-intestinal, cardiovascular, pain management and oncology. It has also its presence in the areas of dermatology, urology and nephrology. As of March 31, 2015, the Company had a total of 260 branded products in India.

In Europe, the Company operates in Germany, the United Kingdom and other Countries within Europe. In Germany, it sells a range of generic pharmaceutical products under the betapharm brand. It markets its generic products in the United Kingdom and other EU countries through its United Kingdom subsidiary, Dr. Reddy's Laboratories (U.K.) Limited. It markets 37 generic products in such countries, representing 89 dosage strengths. In the United States, it sells generic drugs that are the chemical and therapeutic equivalents of reference branded drugs, sold under their generic chemical names at prices below those of their brand drug equivalents. Dr. Reddy's Laboratories, Inc., its wholly owned subsidiary in Princeton, New Jersey, United States, is primarily engaged in the marketing of its generic products in the United States. Its over-the-counter (OTC) division markets and distributes store brand OTC products. It operates in other countries of the former Soviet Union, including Ukraine, Kazakhstan, Belarus and Uzbekistan.

Pharmaceutical Services and Active Ingredients (PSAI)

The Company's Pharmaceutical Services and Active Ingredients (PSAI) segment includes its business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption, such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes its contract research services business, and its manufacture and sale of steroids in accordance with specific customer requirements. During the year ended March 31, 2015, it filed 77 Drug Master Files (DMFs) across the world, of which 12 were filed in the United States, 16 were filed in Europe and 49 were filed in other countries. Its total DMFs filed across the world as of March 31, 2015 were 735, including 219 DMFs filed in the United States. It produces and markets more than 100 different APIs for numerous markets. Its PSAI segment's API business also manufactures and supplies the API requirements of the Company's pharmaceutical services business.

Proprietary Products

The Company's Proprietary Products segment consists of its differentiated formulations business, its new chemical entities (NCEs) business, and its dermatology focused specialty business operated through Promius Pharma. As of March 31, 2015, it had 18 active products in its Proprietary Products development pipeline in various stages of development. In its Proprietary Products segment, its business model focuses on building a pipeline in therapeutic areas of dermatology and neurology.

Promius Pharma LLC (Promius Pharma) is the Company's subsidiary in Princeton, New Jersey in the United States focusing on its United States Specialty Business, which is engaged in the development and sales of branded specialty products in the therapeutic areas of dermatology and neurology. Promius Pharma has a portfolio of in-licensed patented dermatology products. It also has an internal pipeline of dermatology products that are in different stages of development. Promius Pharma's portfolio contains products for the treatment of seborrheic dermatitis, acne and steroid responsive dermatoses. Promius Pharma has commercialized five products: EpiCeram, which is a skin barrier emulsion for the treatment of atopic dermatitis; Scytera, which is foam for the treatment of psoriasis; Promiseb, which is a cream for the treatment for seborrheic dermatitis; Cloderm (clocortolone pivalate 0.1%), which is a cream used for treating dermatological inflammation, and Trianex, which is a cream for the treatment of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

The Company competes with Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Alkem Limited, Mankind Pharma Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited, Emcure Pharmaceuticals Limited, Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Limited, Ranbaxy Laboratories Limited, Nycomed International Management GmbH, Sanofi-Aventis S.A., Mylan Inc., Actavis Inc., Novartis Pharma A.G., Par Pharmaceuticals, Sun Pharmaceuticals Limited, Perrigo, Winthrop Arzneimittel GmbH, Stada Arzneimittel AG, Divis Laboratories Limited, Aurobindo Pharma Limited, Mylan Laboratories Limited, MSN Laboratories Limited, Dishman Pharmaceuticals & Chemicals Limited, Jubilant Organosys Limited, Nicholas Piramal India Limited, Lonza Group, Koninklijke DSM N.V., Albany Molecular Research, Inc., Patheon, Inc. and Cardinal Health, Inc.

Company Address

Dr.Reddy's Laboratories Ltd

8-2-337, Road No.3, Banjara Hill
HYDERABAD     500034
P: +9140.49002900
F: +9140.49002999

Company Web Links

Search Stocks